Skip to content
Evigrade
CriticalFirst-generation antipsychotic, aliphatic-side-chain phenothiazine×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone itself causes mild to moderate, dose-dependent QT prolongation. At the highest recommended dose of 160 mg a day, it increased the heart-rate-corrected QT interval (QTc) by about 10 ms more than placebo (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and ziprasidone label, US Food and Drug Administration, FDA). Phenothiazine neuroleptics, the group that includes chlorpromazine, can intensify QT prolongation, which raises the risk of serious ventricular arrhythmias of the torsade de pointes type that can end in sudden death (chlorpromazine SmPC, AEMPS). No studies have been done with ziprasidone and other QT-prolonging drugs, and an additive effect on QT cannot be excluded (ziprasidone SmPC, AEMPS, and label, FDA). The Spanish chlorpromazine SmPC also says that the risk of arrhythmias rises with such drugs (chlorpromazine SmPC, AEMPS). About two-thirds of ziprasidone is metabolised by reduction involving aldehyde oxidase, and among CYP enzymes, CYP3A4 is the main one. Chlorpromazine strongly inhibits a different enzyme, CYP2D6 (ziprasidone and chlorpromazine SmPCs, AEMPS). Ziprasidone has little inhibitory effect on the major CYP enzymes (FDA ziprasidone label), and the documents give no data on how one drug changes the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes palpitations, dizziness or fainting and can lead to cardiac arrest. Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia. Post-marketing reports describe infrequent cases of torsade de pointes in people taking ziprasidone who had several confounding risk factors (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With chlorpromazine, QT prolongation that can trigger a ventricular arrhythmia is a common adverse reaction. Ventricular fibrillation, ventricular tachycardia, torsade de pointes, cardiac arrest and sudden death have also been reported (chlorpromazine SmPC, AEMPS). The risk of arrhythmia is higher with a slow heart rate, low potassium or magnesium, and congenital QT prolongation (ziprasidone label, US Food and Drug Administration, FDA, and chlorpromazine SmPC, AEMPS).

Management

The combination is contraindicated. The US ziprasidone label states that ziprasidone should not be given with QT-prolonging drugs and names chlorpromazine on this list (ziprasidone label, US Food and Drug Administration, FDA). The Spanish summaries of product characteristics (SmPCs) are less strict: the ziprasidone SmPC says ziprasidone should not be given with QT-prolonging drugs, and the chlorpromazine SmPC does not recommend chlorpromazine with such drugs (ziprasidone and chlorpromazine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Chlorpromazine is not among the drugs named in the Spanish ziprasidone SmPC, but its own SmPC describes QT prolongation (chlorpromazine SmPC, AEMPS). Ziprasidone is contraindicated in known QT prolongation, congenital long QT syndrome, recent acute myocardial infarction and uncompensated heart failure. Correct low potassium and magnesium before starting treatment (ziprasidone SmPC, AEMPS). Before starting chlorpromazine, when the clinical situation allows, rule out a heart rate below 55 beats per minute, low potassium, congenital QT prolongation and current use of QT-prolonging drugs. Except in emergencies, include an electrocardiogram (ECG) in the initial assessment before neuroleptic treatment (chlorpromazine SmPC, AEMPS). If the corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends interrupting ziprasidone treatment. Use ziprasidone with caution together with other centrally acting drugs (ziprasidone SmPC, AEMPS). No document states how long to wait between stopping one drug and starting the other. The mean half-life of oral ziprasidone is 6.6 hours, and that of chlorpromazine is about 30 hours, with wide variation (ziprasidone and chlorpromazine SmPCs, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Chlorpromazine

Other interactions with Ziprasidone